Antivascular therapy after recurrence of glioblastoma: anlotinib vs bevacizumab

Antivascular therapy after recurrence of glioblastoma: anlotinib vs bevacizumab

ZHOU Jin, LIU Haoyun, ZHANG Haoyu, YANG Xinyue, WANG Ruizhi, HUANG Renhua

PDF(1444 KB)

Tumor website：www.tumorsci.org E-mail Alert

PDF(1444 KB)

Tumor ›› 2024, Vol. 44 ›› Issue (09) : 971-978. DOI: 10.3781/j.issn.1000-7431.2024.2402-0089

Original Research

Antivascular therapy after recurrence of glioblastoma: anlotinib vs bevacizumab

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2024, 44(09): 971-978 https://doi.org/10.3781/j.issn.1000-7431.2024.2402-0089

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}

{{article.copyrightLicense_en}}

PDF(1444 KB)

Accesses

Citation

Detail

Sections

Recommended

/

〈

〉